Rani Therapeutics Holdings (RANI) Interest Coverage Ratio Growth (3y) (2023 - 2026)
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Interest Coverage Ratio Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 13.52% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -98.43% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 29.79% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 44.22% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 33.30% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | -324.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -324.26% |
| Mar 31, 2026 | -90.61% |
| Dec 31, 2025 | -0.39% |
| Sep 30, 2025 | 40.04% |
| Dec 31, 2024 | -26.01% |
| Sep 30, 2024 | 67.31% |
| Jun 30, 2024 | 31.93% |
| Mar 31, 2024 | 26.80% |
| Dec 31, 2023 | 50.46% |
| Sep 30, 2023 | 32.53% |
| Jun 30, 2023 | 79.57% |